For example, in an experimental study in 2016 in mice, using Linagliptin, a DPP-4 inhibitor, was associated with upregulation of stromal cell-derived Factor-1, which contributes as an antioxidative and anti-fibrotic agent in the pathophysiology of diabetic nephropathy [42]. Here, DPP4 is linked to diabetic kidney disease.